Related Experiment Video
Updated: Jul 7, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Linezolid for treatment of subdural empyema due to Streptococcus: case reports
Laurent Lefebvre1, Philippe Metellus, Henry Dufour
1Department of Anesthesiology and Intensive Care, CHU Timone, Université de la Méditerranée, Marseille, France.
Background:
Recurring subdural empyema despite adequate surgical drainage and antibiotic treatment is still a life-threatening disease. This is mainly due to poor diffusion of the antibiotic into the subdural space.
Case Description:
We report 2 cases of recurring subdural empyema due to Streptococcus, after repeat surgery and high-dose antibiotic treatment including beta-lactamines and vancomycin. Both patients showed marked clinical and radiologic improvement after introduction of linezolid. There was no drug-related adverse effect despite 36 and 90 days of treatment.
Conclusion:
Off-label use of linezolid for treatment of subdural empyema due to gram-positive bacteria should be considered after failure of conventional antibiotic treatment.
Insights
Recurrent subdural empyema, a serious infection, may improve with linezolid when standard antibiotics fail. This antibiotic showed efficacy and safety in two challenging cases.
Area of Science:
- Neuroscience
- Infectious Diseases
- Pharmacology
Background:
- Recurring subdural empyema is a life-threatening condition.
- Poor antibiotic diffusion into the subdural space complicates treatment.
- Conventional therapies often prove insufficient.
Observation:
- Two cases of recurrent subdural empyema caused by Streptococcus are presented.
- Patients received high-dose beta-lactamines and vancomycin with repeat surgeries.
- Linezolid was introduced due to persistent infection.
Findings:
- Both patients experienced significant clinical and radiological improvement after linezolid administration.
- Linezolid treatment lasted 36 and 90 days respectively.
- No drug-related adverse effects were observed.
Implications:
- Linezolid offers a potential treatment option for refractory subdural empyema.
- Consider off-label linezolid use for gram-positive bacterial empyema post-conventional therapy failure.
- Further research into linezolid's role in CNS infections is warranted.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Rocky Mountain Spotted Fever
Brain Abscess l: Introduction
Clinical Significance of Antibiotic Resistance
Streptococcal Pharyngitis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...